Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope National Medical Center,
Duarte, California, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- the Angeles Clinic & Research Institute
Los Angeles, California, United States
- John Wayne Cancer Institute
Santa Monica, California, United States
- Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- Advocate Health, Sc
Park Ridge, Illinois, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Atlantic Melanoma Center
Morristown, New Jersey, United States
- Providence Portland Medical Center
Portland, Oregon, United States
- Huntsman Cancer Institute
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 May 2015
- Primary completion
- 5 Nov 2019
- Completion
- 5 Nov 2019
- Last update posted
- 17 Jan 2023
- Registered enrollment
- 50
- Registry id
- NCT02307149
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.